DPLO - Diplomat Pharmacy, Inc.

NYSE - Nasdaq Real Time Price. Currency in USD
4.0000
+0.0100 (+0.25%)
As of 4:02PM EST. Market open.
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close3.9900
Open4.0000
Bid0.0000 x 800
Ask0.0000 x 800
Day's Range4.0000 - 4.0100
52 Week Range2.4300 - 6.8400
Volume514,785
Avg. Volume0
Market Cap303.991M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateAug 07, 2020 - Aug 11, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.39
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Generac Holdings Set to Join S&P MidCap 400; Alexander & Baldwin and America's Car-Mart to Join S&P SmallCap 600
    PR Newswire

    Generac Holdings Set to Join S&P MidCap 400; Alexander & Baldwin and America's Car-Mart to Join S&P SmallCap 600

    S&P; Dow Jones Indices will make the following changes to the S&P; MidCap 400 and S&P; SmallCap 600 effective prior to the open of trading on Thursday, February 13:

  • ACCESSWIRE

    SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Diplomat Pharmacy, Inc. - (NYSE: DPLO)

    BALA CYNWYD, PA / ACCESSWIRE / December 18, 2019 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Diplomat Pharmacy, Inc. ("Diplomat" ...

  • Is Diplomat Pharmacy Inc (DPLO) A Good Stock To Buy?
    Insider Monkey

    Is Diplomat Pharmacy Inc (DPLO) A Good Stock To Buy?

    Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]

  • ACCESSWIRE

    INVESTOR ALERT: Monteverde & Associates PC Is Investigating The Following Transaction

    NEW YORK, NY / ACCESSWIRE / December 14, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New ...

  • SHAREHOLDER ALERT: WeissLaw LLP Investigates Diplomat Pharmacy, Inc.
    PR Newswire

    SHAREHOLDER ALERT: WeissLaw LLP Investigates Diplomat Pharmacy, Inc.

    WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Diplomat Pharmacy, Inc. ("Diplomat" or the "Company") (NYSE: DPLO) in connection with the proposed acquisition of the Company by UnitedHealth Group's (NYSE: UNH) OptumRx. Under the terms of the acquisition agreement, DPLO shareholders will receive $4 per share in cash.

  • DIPLOMAT ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of DPLO and Encourages Investors to Contact the Firm
    PR Newswire

    DIPLOMAT ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of DPLO and Encourages Investors to Contact the Firm

    Bragar Eagel & Squire, P.C., a nationally recognized stockholder law firm, has launched an investigation into whether the board members of Diplomat Pharmacy, Inc. (NYSE: DPLO) breached their fiduciary duties or violated the federal securities laws in connection with the company's proposed sale to UnitedHealth Group Inc.

  • SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of DIPLOMAT PHARMACY, INC - DPLO
    PR Newswire

    SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of DIPLOMAT PHARMACY, INC - DPLO

    Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Diplomat Pharmacy, Inc. ("Diplomat" or the "Company") (NYSE: DPLO) relating to the sale of the Company to UnitedHealth Group Incorporated. Under the terms of the Merger, Diplomat shareholders will have the right to receive $4.00 in cash for each Diplomat common stock owned.

  • Moody's

    Diplomat Pharmacy, Inc. -- Moody's reviews Diplomat Pharmacy for upgrade

    Moody's Investors Service ("Moody's") placed the ratings of Diplomat Pharmacy, Inc. ("Diplomat") under review for upgrade. Moody's changed the outlook to rating under review from developing. OptumRx is part of UnitedHealth Group Incorporated, which has senior unsecured debt rated A3 with a stable outlook.

  • M&A Monday in healthcare: Merck, Sanofi, UnitedHealth
    Reuters Videos

    M&A Monday in healthcare: Merck, Sanofi, UnitedHealth

    M&A Monday in healthcare, with two of the deals involving cancer drugs. Merck is buying ArQule for $2.7 billion. It's the latest move by a U.S. drug maker to buy targeted cancer therapies. The deal strengthens Merck's oncology business well before its blockbuster cancer drug Keytruda loses its market exclusivity in 2028. ArQule's crown jewel that Merck wants is a precision drug that tailors treatment to a patient's genetic profile. California's biotech firm Synthorx is getting $2.5 billion in cash, selling itself to France's Sanofi. Synthorx focuses on therapies for people with cancer or auto-immune disorders. Sanofi is stepping up its drive to expand into cancer drugs under its new chief executive. Like Merck, Sanofi is also paying a rich premium. UnitedHealth, by contrast, is buying Diplomat Pharmacy at a 31% discount. Diplomat has been losing customers in its pharmacy benefits management business due to intense competition. Shares of acquirers Merck, Sanofi and UnitedHealth fell, while Arqule and Synthorx shares doubled in early trading. Diplomat shares plunged more than 30%.

  • Benzinga Pro's Top 5 Stocks To Watch For Mon., Dec. 9, 2019: MRK, PCG, M, DPLO, CHWY
    Benzinga

    Benzinga Pro's Top 5 Stocks To Watch For Mon., Dec. 9, 2019: MRK, PCG, M, DPLO, CHWY

    Benzinga Pro's Stocks To Watch For Monday Merck (MRK)  - Reported it will purchase  ArQule (ARQL)  in a deal valued at $2.7 billion. The purchase price for ArQule was $20/share in cash. ArQule shares were ...

  • Benzinga

    UnitedHealth To Buy Diplomat Pharmacy For $300M

    Diplomat Pharmacy (NYSE: DPLO ) shares are trading lower on Monday after the company received a $4 per share acquisition offer from UnitedHealth Group's (NYSE: UNH ) OptumRx. Optum is UnitedHealth Group's ...

  • UnitedHealth's Optum will take over Diplomat Pharmacy in $300 million deal
    American City Business Journals

    UnitedHealth's Optum will take over Diplomat Pharmacy in $300 million deal

    UnitedHealth Group Inc. said Monday it will spend about $300 million to acquire Diplomat Pharmacy Inc., a specialty pharmacist that had been struggling to compete in an industry increasingly dominated by health-industry giants.

  • Reuters

    UPDATE 2-Diplomat Pharmacy agrees to $300 million buyout by UnitedHealth

    Diplomat Pharmacy Inc on Monday agreed to UnitedHealth Group Inc's over $300 million buyout offer, weeks after it warned of its inability to pay off some of its debt amid intense competition in the pharmacy benefits management business. Health insurer UnitedHealth's offer of $4 per share in cash is at a 31% discount to Diplomat's closing price on Friday and is a far cry from the company's peak market valuation in 2015, when its shares had traded as high as $52. "It's hard for me to call it (UnitedHealth's offer) a godsend on a stock that has gone from over $50 to now a take-under... I would not call this a great day for Diplomat," Baird analyst Eric Coldwell told Reuters.

  • TheStreet.com

    UnitedHealth to Buy Diplomat Pharmacy for $4 a Share, Combine Firm With OptumRx

    Diplomat, the Flint, Mich., pharmacy- and infusion-services provider, had considered a number of strategic options.

  • Implied Volatility Surging for Diplomat Pharmacy (DPLO) Stock Options
    Zacks

    Implied Volatility Surging for Diplomat Pharmacy (DPLO) Stock Options

    Investors need to pay close attention to Diplomat Pharmacy (DPLO) stock based on the movements in the options market lately.

  • Company News for Nov 29, 2019
    Zacks

    Company News for Nov 29, 2019

    Companies In The News Are: CENT, BOX, DPLO, EVH

  • Diplomat Pharmacy, Inc. Just Reported And Analysts Have Been Cutting Their Estimates
    Simply Wall St.

    Diplomat Pharmacy, Inc. Just Reported And Analysts Have Been Cutting Their Estimates

    Diplomat Pharmacy, Inc. (NYSE:DPLO) investors will be delighted, with the company turning in some strong numbers with...

  • Thomson Reuters StreetEvents

    Edited Transcript of DPLO earnings conference call or presentation 12-Nov-19 1:30pm GMT

    Q3 2019 Diplomat Pharmacy Inc Earnings Call

  • Benzinga

    Diplomat Pharmacy Analysts Weigh Takeout Scenarios, Valuation After Going Concern Warning

    Diplomat Pharmacy Inc (NYSE: DPLO) cautioned investors on Tuesday that it has "substantial doubts" related to its ability to continue functioning as a business. Wells Fargo analyst Jamie Stockton maintained a Market Perform rating on Diplomat with a price target lowered from $5.50 to $3. If the company opts not to sell itself and remain public, it would be valued at eight times EV/EBITDA on EBITDA estimates of $85 million, the analyst said.

  • Benzinga

    The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 12) ACADIA Pharmaceuticals Inc (NASDAQ: ACAD ) Allergan ...

  • Moody's

    Diplomat Pharmacy, Inc. -- Moody's downgrades Diplomat Pharmacy to Caa1; developing outlook

    Moody's Investors Service ("Moody's") downgraded the ratings of Diplomat Pharmacy, Inc. ("Diplomat") including the Corporate Family Rating to Caa1 from B3, the Probability of Default Rating to Caa1-PD from B3-PD, the senior secured rating to Caa1 from B3 and the Speculative Grade Liquidity Rating to SGL-4 from SGL-3. The downgrade of the Corporate Family Rating to Caa1 from B3 reflects the recent decision by a large payer to begin excluding Diplomat from its specialty pharmacy network later this month, raising concerns about Diplomat's competitive position.

  • Benzinga

    Diplomat Pharmacy Has 'Substantial Doubt' It Can Continue Operations

    Shares of Diplomat Pharmacy, Inc. (NYSE: DPLO), a Flint, Michigan-based independent provider of specialty pharmacy and infusion services, plummeted more than 50% Tuesday after the company warned investors it faces an existential threat. Revenue declined year-over-year from $1.373 billion to $1.301 million, and the pharmacy benefit manager segment revenue fell from $170 million to $82 million as the segment's total volume fell from 1,931,000 to 922,000. Diplomat's earnings report includes a warning that it may not be able to meet its total net leverage and interest coverage ratio covenants as part of its credit agreement for the period ending Dec. 31, 2019.

  • Diplomat Pharmaceuticals (DPLO) Reports Q3 Loss, Tops Revenue Estimates
    Zacks

    Diplomat Pharmaceuticals (DPLO) Reports Q3 Loss, Tops Revenue Estimates

    Diplomat Pharmaceuticals (DPLO) delivered earnings and revenue surprises of -40.00% and 11.81%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Diplomat Announces 3rd Quarter Financial Results; Updates 2019 Guidance
    PR Newswire

    Diplomat Announces 3rd Quarter Financial Results; Updates 2019 Guidance

    3rd Quarter Revenue of $1,301 Million , compared to $1,373 Million , Net Loss of $177 Million , compared to Net Income of $0.2 Million , Adjusted EBITDA of $11.5 Million , compared to $41.9 Million FLINT, ...

  • Hedge Funds Have Never Been Less Bullish On Diplomat Pharmacy Inc (DPLO)
    Insider Monkey

    Hedge Funds Have Never Been Less Bullish On Diplomat Pharmacy Inc (DPLO)

    The 700+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the second quarter, which unveil their equity positions as of June 28. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]